Skip to content
Medical Health Aged Care

New Monash study represents major steps forward to reduce Australia’s unintended pregnancies

Monash University 2 mins read

The newly published ACCORd follow up study by Monash University’s SPHERE Centre of Research Excellence will help address Australia’s chronically low use of the most effective types of contraception, long acting reversible contraceptives (LARC), and high number of unintended pregnancies. 

Australian LARC use sits around 11 per cent, compared to countries like Sweden, other parts of Europe and the United Kingdom, which have over 30 per cent use.

In Australia, one in four women experience an unintended pregnancy, and a third of those end in abortion. It is higher amongst women aged 18-32 years and those living in non-urban areas. 

The ACCORd trial involved training GPs in contraceptive counselling and providing them with a rapid pathway to a LARC inserter.  Results were published in 2020 and demonstrated much higher rates of LARC uptake in women attending these GPs.

The follow up study, published this month in the American Journal of Obstetrics and Gynecology checked in with the women after three years.

Of the original ACCORd trial, 75 per cent of participants agreed to take part in the follow-up study. At three years, the continuation rate of long-acting reversible contraception was 66 per cent, significantly higher than for non-LARC methods at 55 per cent. 

Satisfaction with their method of contraception was higher among LARC users compared to oral contraceptive pill users. 

LARC use at three years was also significantly higher among women attending the Intervention GPs (41 per cent) compared to 28 per cent in women attending control GPs.  

Participants who consulted with the Intervention GPs experienced significantly fewer unintended pregnancies – 3.1 per cent compared to 6.3 per cent for participants who received regular advice– and also fewer abortions at 0.9 per cent compared to 3.6 per cent.

The Head of Monash University’s Department of General Practice and SPHERE Director, Professor Danielle Mazza, said the ACCORd project has far reaching implications for contraception in Australia.

“The results demonstrate that GP training in contraceptive counselling and the opportunity to rapidly refer women for LARC insertion if GPs don’t provide that service themselves has a long-term sustained impact on the continuation rate of LARC methods, and reduces the numbers  of unintended pregnancies and abortion,” Professor Mazza said. 

 

“The ACCORd trial and follow up study has informed the Federal Government’s recent announcement of additional LARC training centres of excellence, training opportunities and financial incentives for GPs and other primary care practitioners, and subsidies that significantly lower the cost for women to access these methods.” 

 

The ACCORd project, conducted by SPHERE, comprised two major studies:

  1. ACCORd Trial: A trial to train GPs in contraceptive counselling and provide rapid insertion of LARC devices – involving 57 GPs and 740 women. The results were published in 2020.
  2. ACCORd Follow-up Study: A three-year follow-up with women participants to assess their ongoing use of LARCs involving 75 per cent of the original group of women.

Read the full paper in American Journal of Obstetrics and Gynecology: “Increasing the uptake of long-acting reversible contraception through family practice: the Australian Contraceptive ChOice pRoject (ACCORd) cluster randomized controlled trial 3-year follow-up”

 

DOI: https://doi.org/10.1136/bmjopen-2019-035895

 

 

For media enquiries please contact:

Monash University

Helena Powell – Media Advisor (medical)
E: [email protected] 

T: +61 (0) 474 444 171

 

For more Monash media stories, visit our news and events site  


For general media enquiries please contact:
Monash Media
E: [email protected]
T: +61 (0) 3 9903 4840

More from this category

  • Medical Health Aged Care
  • 12/12/2025
  • 10:11
Cosette Pharmaceuticals, Inc.

Termination of Proposed Acquisition of Mayne Pharma

BRIDGEWATER, N.J.–BUSINESS WIRE– Cosette Pharmaceuticals, Inc. (Cosette), a U.S.-based, fully integrated pharmaceutical company, confirms that on 9 December 2025 it served a notice on…

  • Contains:
  • Medical Health Aged Care
  • 12/12/2025
  • 08:55
Royal Australian College of GPs

Universal Health Coverage Day: RACGP calls out need for better funding for chronic conditions and preventive care

Specialist GPs have marked International Universal Health Coverage (UHC) Day by joining the World Health Organization in highlighting the devastating impact of health costs. The Royal Australian College of GPs (RACGP) has stressed that a public health system which forces patients with complex or chronic conditions to pay out of pocket for longer consultations can’t claim to offer universal coverage, and urged governments to protect patients from financial hardship. “Health is a human right,” RACGP President Dr Michael Wright said. “Australia recognises the right of everyone to the highest attainable standard of physical and mental health, and our governments are…

  • Contains:
  • Medical Health Aged Care, Women
  • 12/12/2025
  • 01:00
Breast Cancer Trials

Simple blood tests could help tailor treatment for aggressive breast cancer

Key Facts: Blood tests detecting circulating tumour DNA could help guide treatment for triple negative breast cancer patients Absence of tumour DNA in blood…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.